Cancer is one of the deadliest and most spread diseases in our time. Breast cancer is especially deadly and affects about 1 in every 8 women in the USA. It is the second major cause of death in women after lung cancer and there’s been no advancements in the search for a cure until now.
Recently, Professor Nigel Bundred uncovered a major breakthrough in the search for a cure for breast cancer at the European Breast Cancer Conference held in Amsterdam.
According to his team, Lapatinib and Herceptin (Trastuzumab), drugs used in treatments prior to chemotherapy can kill breast cancer cells in only 11 days!
The study was funded by Cancer Research UK, and examined how these drugs react to a protein called HER2, which is responsible for the development of breast cancer cells. A total of 257 women with breast cancer volunteered in the study and were divided into two groups. The first received treatment with Lapatinib and Herceptin, while the second group was the control group.
After just 2 weeks, 11% of the women from the first group had no traces of cancer cells, while 17% of them experienced a significant reduction in their tumors. The control group had no improvements and only 3% of the women had reduced tumors in 2 weeks.
At the moment, Herceptin seems to be only available under chemotherapy, which causes adverse side-effects as loss of hair, fatigue, vomiting and headaches. However, this recent discovery is literally a light in the dark. Over time, it may lead to new policies on treating cancer, and we may end up using these drugs as the primary cancer therapy.